As highlighted in the Introduction, much of the improvements in CF clinical care prior to the development of CFTR modulators were delivered through multidisciplinary team approaches which already have experience in managing multimorbidity and polypharmacy and are therefore already well positioned to manage an ageing population. This evidence concerns the gene CFTR and cystic fibrosis.